2010
DOI: 10.3748/wjg.v16.i44.5582
|View full text |Cite
|
Sign up to set email alerts
|

Screening compounds against HCV based on MAVS/IFN-β pathway in a replicon model

Abstract: Our data show that this reporter system is a sensitive and quantitative reporter of anti-HCV inhibitors. This system will constitute a new tool to allow the efficient screening of HCV inhibitors.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2012
2012
2012
2012

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 30 publications
0
1
0
Order By: Relevance
“…The NS3/4A protein also blocks RLH signaling by directly cleaving MAVS at Cys-508, displacing it from the OMM [3,102,103]. Notably, current screenings for new HCV therapeutics are targeting this mitochondria-localized phenomenon of MAVS cleavage, and the virus’ ability to overcome innate immune recognition from host cells [104]. …”
Section: Mitochondrial Innate Immune Signalingmentioning
confidence: 99%
“…The NS3/4A protein also blocks RLH signaling by directly cleaving MAVS at Cys-508, displacing it from the OMM [3,102,103]. Notably, current screenings for new HCV therapeutics are targeting this mitochondria-localized phenomenon of MAVS cleavage, and the virus’ ability to overcome innate immune recognition from host cells [104]. …”
Section: Mitochondrial Innate Immune Signalingmentioning
confidence: 99%